Organic compounds -- part of the class 532-570 series inventions 11/07

20070276134 - Compositions and methods for complexes of nucleic acids and organic cations: What is described is a stable double stranded (ds) nucleic acid molecule composition, comprising a dsRNA molecule complexed with an organic cation.... Agent: Nastech Pharmaceutical Company Inc

20070276133 - 5-hydroxytryptophol (5-htol) derivatives, antibodies, immunoassays and detection of recent alcohol consumption: Antibody specific for a 5-HTOL compound. A glucuronide with 5-hydroxytryptophol (5-HTOL) characterized in that it comprises the structure of the β-glucuronide between the 5-hydroxy group of 5-HTOL and D-glucopyranosiduronic acid. An immunoassay and a diagnostic method utilizing the immunoassay wherein a 5-hydroxytryptophol (5-HTOL) compound is determined by the use of... Agent: Bacon & Thomas, PLLC

20070276135 - Sirna targeting dual specificity phosphate 5 (dusp5): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070276136 - Sirna targeting serine/threonine kinase 12 (stk12 or aurora b kinase): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070270578 - Plants having increased yield and a method for making the same: The present invention concerns a method for increasing plant yield by increasing activity in a plant of an Os-MADS18-like polypeptide or a homologue thereof. One such method comprises introducing into a plant an OsMADS18-like nucleic acid or variant thereof. The invention also relates to transgenic plants having introduced therein an... Agent: Connolly Bove Lodge & Hutz, LLP

20070270580 - Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same: Provided are methods of identifying oligonucleotides having transcriptional or translational activity by integrating ilie oligonucleotide into a eukaryotic cell genome such that the oligonucleotide is operatively linked to an expressible polynucleotide, and detecting a change in expression of the expressible polynucleotide due to the operatively linked oligonucleotide. Also provided are... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20070270579 - Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating gene expression using short interfering nucleic acid (siNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20070270581 - Stable tablet formulation: The present invention is directed to a stable solid formulations of tetrahydrobiopterin, processes for producing them, and treatment methods using such formulations.... Agent: Marshall, Gerstein & Borun LLP

20070270582 - Nucleoside releasing functional unit through oxidation and process for producing oligonucleotide containing thereof: (wherein each of X and Y independently represents —O—, —NH—, —N(alkyl)- or —S—; R represents a functional unit, a reporter unit or a biofunctional molecule; each of R1 and R2 independently represents a hydrogen atom, a phosphate bond group, a phosphoramidite group or a nucleotide; and n is a numeral... Agent: Rader Fishman & Grauer PLLC

20070270583 - Process for purification of 6 acetyl 4,1', 6' trichlorogalactosucrose and 4,1', 6' trichlorogalactosucrose by chromatography on silanized silica gel: A reverse phase column chromatographic process of purification of 6-acetyl-4,1′,6′trichlorogalactose and 4,1′,6′trichlorogalactose is described which uses silanized silica as stationary phase and water or predominatly aqeous mixture derived from water and small proportion of organic solvents as a mobile phase.... Agent: Nath & Associates

20070265434 - Simplified method to retrieve chitosan from acidic solutions thereof: Composition of salted out chitosan polymer containing mixture of certain salting out salts as well as methods for making and using same are disclosed. Chitosan polymer preparations produced by such methods are substantially free of chitosanase, undesirable salts and excess acid and retain their physiological as well as biological and... Agent: Choate Hall & Stewart

20070265436 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Heller Ehrman LLP

20070265435 - Process for the synthesis of oligomeric compounds: Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, phosphorodithioate, or other covalent linkages. The oligomers have substantially reduced exocyclic adducts deriving from acrylonitrile or related contaminants.... Agent: Woodcock Washburn LLP

20070265438 - Sirna targeting polo-like kinase-1 (plk-1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070265437 - Sirna targeting testes development-related nyd-sp21 (nyd-sp21): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070265439 - Method for controlling valves during the thermocyclisation of a substance for the purpose of polymer chain reaction (pcr) and associated arrangement: At least one embodiment of the invention relates to an arrangement for thermocyclisation of a substance. At least one embodiment of the invention also relates to a method for the thermocyclisation of a substance, including: the controllable valves automatically close the PCR chamber after the test fluid has been introduced... Agent: Harness, Dickey & Pierce, P.L.C

20070265440 - Methods and compositions for treating inflammatory response: Compositions for oral administration of compounds having A2A adenosine receptor antagonist activity are provided. These compositions are useful for treatment of inflammatory conditions.... Agent: Schwegman, Lundberg & Woessner, P.A.

20070265441 - Apparatus and methods for the automated synthesis of oligosaccharides: One aspect of the present invention relates to an apparatus for the efficient synthesis of oligosaccharides on a solid support, e.g., formed by subunit addition to terminal subunits immobilized on solid-phase particles. In certain embodiments, the apparatus of the present invention is used in combinatorial methods, e.g., as described herein,... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070260047 - Sirna targeting eph receptor a4 (epha4): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070260048 - Sirna targeting centromere protein e, 312kda (cenpe): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070260049 - Sirna targeting mad2 mitotic arrest deficient-like (mad2l2): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070260050 - Sirna targeting minichromosome maintenance deficient 7 (mcm7): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070260051 - Sirna targeting pituitary tumor-transforming 1 (pttg1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070260052 - Sirna targeting rad1 homolog (rad1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070260053 - Method for generating transcripts: The present invention relates to a method for generating transcripts from: at least one RNA sequence to be amplified comprising a “primer” region and a region of interest, and an amplification primer comprising a promoter region, and a region capable of hybridizing to said “primer” region of the RNA sequence... Agent: Oliff & Berridge, PLC

20070260054 - Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof: Low molecular weight hydrophobic derivatives of non-cyclic α(1→4)glucopyranose polymers and non-reducing polysaccharides are described. The derivates can be used to form matrices in various forms, including body members of implantable articles, coatings, and consumer items, which have desirable properties.... Agent: Kagan Binder, PLLC

20070255045 - Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging: Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.... Agent: Dann, Dorfman, Herrell & Skillman

20070255047 - Sirna targeting cell division cycle 6 homolog (cdc6): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070255048 - Sirna targeting discoidin domain receptor family, member 1 (ddr1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070255049 - Sirna targeting eph receptor a3 (epha3): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070255050 - Sirna targeting minichromosome maintenance deficient 2, mitotin (mcm2): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070255051 - Sirna targeting serine/threonine kinase 22b (stk22b): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070255046 - Sirna targeting spectrin sh3 domain binding protein 1 (ssh3bp1): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070255052 - Sirna targeting v-myc myelocytomatosis viral oncogene homolog (myc): Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20070255053 - Random-primed reverse transcriptase - in vitro transcription method for rna amplification: A random-primed reverse transcriptase-in vitro transcription method of linearly amplifying RNA is provided. According to the methods of the invention, source RNA (or other single-stranded nucleic acid), preferably, mRNA, is converted to double-stranded cDNA using two random primers, one of which comprises a RNA polymerase promoter sequence (“promoter-primer”), to yield... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070255054 - Oligonucleotide synthesis with intermittent and post synthetic oxidation: Process for fabricating an array of polymers on a solid support is provided having the steps of coupling a monomer with a reactive side masked by a protecting group to a growing polymer chain, optionally capping the monomer or monomer chains that have not reacted in a given cycle, deprotecting... Agent: Affymetrix, Inc Attn: ChiefIPCounsel, Legal Dept.